Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase.
Hatzelmann
A
A
Institute for Cardiovascular and Arteriosclerosis Research, Bayer AG, Wuppertal, Germany.
Fruchtmann
R
R
Mohrs
K H
KH
Raddatz
S
S
Matzke
M
M
Pleiss
U
U
Keldenich
J
J
Müller-Peddinghaus
R
R
D058927:5-Lipoxygenase-Activating Proteins; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D001667:Binding, Competitive; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology*
D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; D002352:Carrier Proteins; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D011804:Quinolines; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; D001094:Arachidonate 5-Lipoxygenase